arGEN-X
argenx SE, operating legally as argenx NV, is an international biotechnology company focused on developing antibody-based therapies for autoimmune diseases and cancer. The company utilizes its proprietary SIMPLE Antibody platform to discover and commercialize human monoclonal antibody treatments. Its primary revenue driver is global sales of Vyvgart (efgartigimod), an approved neonatal Fc receptor blocker used to treat generalized myasthenia gravis and related autoimmune conditions. End markets primarily comprise specialized hospital networks, neurology clinics, and immunology medical practices across North America, Europe, and Asia-Pacific. argenx occupies a leading commercial position among commercial-stage European biotechnology firms specializing in rare autoimmune disorders. The company maintains operational headquarters in Ghent, Belgium, and legal domicile in the Netherlands, with listings on Euronext Brussels and the Nasdaq under the ticker symbol ARGX.
46 of the funds FundTelligence covers report a position in arGEN-X.
- Legal name
- arGEN-X N.V.
- Sector
- Health Care
- Country
- Belgium
- Funds holding it
- 46
Funds holding arGEN-X
- Nordea Global Social Empowerment — Nordea Funds · 3.85 % (full portfolio disclosed, September 2026)
- Lannebo Global Growth — Lannebo · 3.04 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 2.88 % (full portfolio disclosed, October 2026)
- Nordea Fremtid — Nordea Funds · 2.6 % (full portfolio disclosed, September 2026)
- Nordea Global Impact Fund — Nordea Funds · 1.97 % (full portfolio disclosed, September 2026)
- Handelsbanken Helse Tema — Handelsbanken · 1.75 % (full portfolio disclosed, October 2026)
- SEB Läkemedelsfond — SEB · 1.36 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.22 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 46 funds holding it.